PROCURE BIOBANK
PROCURE BIOBANK
PROCURE BIOBANK
A multicentric biobank
The PROCURE Biobank is the result of more than ten years of collaboration between four university hospital centers in Quebec, with the support of major donors and financial partners.
A biobank dedicated to prostate cancer research
We have collected a considerable amount of biospecimens and data from some 2,000 men who had undergone prostatectomy:
- Prostate tissue, blood and urine at surgery; blood and urine during medical follow-up visits;
- Associated clinical, pathological and socio-demographic data.
Helping research by providing biospecimens and data of great scientific value to better understand prostate cancer, diagnose it earlier and treat it in a targeted and precise manner.
- Biological fluids
- Serum, plasma, buffy coat, PBMC, urine
- Derived samples
- Blood DNA and RNA
- Prostatic tissues
- Frozen in OCT; fixed and paraffin embedded (FFPE)
- Tissue microarrays (TMA)
- Available soon
- Harmonization of operating procedures and methods at the four collection sites;
- Sociodemographic data questionnaire completed by participants;
- Mainly Canadian and French-speaking cohort;
- Full tissue characterization by biobank pathologists;
- Collection of blood and urine at follow-up visits, leading to the possibility of longitudinal studies;
- Update of clinical data during medical follow-up visits
- Number of participants: 2004
- Median medical follow-up: 7 years
- Mean age at diagnosis: 62 +/- 6.4 years
- Mean PSA at diagnosis: 7.9 +/- 10.3 ng/mL
- Biochemical recurrence: 652 patients (33%)
- Cases of cancer resistant to hormone therapy (CRPC): 80 patients (4%)
- Mortality: 187 patients (9%)
To grow, prostate cancer depends on sex hormones, called androgens. Treatment that deprives the production of androgens by chemical or surgical castration is the most effective basic treatment to stop the progression of this cancer. Unfortunately, after a while the cancer becomes “castration resistant”.
Dr. Éric Lévesque and his team are interested in the mechanisms of synthesis of these hormones and in particular the enzymes that produce them as well as the impact of the level of these hormones on the growth of prostate cancer.
The objective of this research project is to analyze in the blood of patients before and after castration and during the progression of their cancer the blood levels of these different hormones and to correlate these levels with the progression of the disease and certain of its characteristics.
In this research project, Dr. Lévesque hopes to be able to demonstrate that the level in the blood of certain of these hormones could predict whether or not patients will rapidly develop resistance to castration. Such information could be used to choose more appropriate treatments in these patients.
A total of 1929 blood samples from the biobank will be used for this project.
Other pages that might interest you
Additional Information - Procure biobank
How I coped with prostate cancer
A man with prostate cancer shares the challenges of his cancer experience.
Urologist’s advice: Treatments and information on prostate cancer
Learn more about the role of the urologist and the importance for a patient to gather adequate information after receiving a prostate cancer diagnosis.
Prostate cancer: Tests, imaging and biomarkers
Discussion about the variety of approaches available to monitor this disease before, during, or after treatment.
Symptoms, risk and screening
Are you over 50 or experiencing urinary problems? Discover why early screening for prostate diseases is important.
Diagnosis and treatment
Recently diagnosed with cancer? Educate yourself to fully understand your situation.
The role of hormone therapy
Has your doctor recommended hormone therapy? This video is for you!
External radiation or Brachytherapy?
Explore the benefits and considerations of each treatment option for prostate cancer to determine which might be right for you.
Q-A – New therapies for advance prostate cancer
In this interview, we answer patients’ questions about new therapies for advanced prostate cancer.
Genetic predisposition to prostate cancer
Although rare, some hereditary genetic mutations can increase your risk of prostate cancer.
Active surveillance in 5 points
As surprising as it may seem, your doctor may prefer to wait before starting treatment.
States of prostate cancer post-treatment
Gentlemen, you’re being treated for prostate cancer, and your latest blood tests show an increase in PSA levels?
Your role as a patient
Have you been diagnosed with prostate cancer? Your role as a patient is essential throughout your journey.
Sources and references
Last medical and editorial review: April 2024. See our web page validation committee and our collaborators by clicking here.
